

Attorney Docket No.: 6520.200.US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgen K. Smedegaard

Serial No.: 10/619,237

Group Art Unit: To Be Assigned

Filed: July 14, 2003

Examiner: To Be Assigned

For: Medical Delivery Device

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 20, 2003

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)



Attorney Docket No.: 6520.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jorgen K. Smedegaard

Application No.: 10/619,237

Group Art Unit: To Be Assigned

Filed: July 14, 2003

Examiner: To Be Assigned

For: Medical Delivery Device

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US Patent No. 5858001
2. US Publication No. 2002/0010423
3. US Patent No. 5672167
4. EP Patent No. 1177802
5. US Patent No. 99/32174
6. US Patent No. 4340048


7. US Patent No. 4552561
8. US Patent No. 6280148
9. US Patent No. 2605765
10. US Patent No. 5957895
11. US Patent No. 5527288
12. US Patent No. 6302869
13. US Patent No. 6074369
14. US Patent No. 5169390
15. Hannele et al., New England Journal of Medicine, 1992, Vol. 327, Pages 1426-1433.
16. Puhakainen I et. al., Diabetes Care, 1994, Vol. 17, Pages 805-809.
17. Kawamori et. al., Diabetes Care, 1989, Vol. 10, Pages 680-685.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,


Date: October 20, 2003



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 5-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6520.200-US

Serial No. 10/619,237

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Jorgen K. Smedegaard

Filing Date July 14, 2003

Group To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5858001	1-12-99	Tsals et al.	604	135	
	02/0010423	1-24-02	Joseph Gruss	604	143	
	5672167	9-30-97	Amulya et al.	604	892.1	
	4340048	7-20-82	Eckenhoff	128	213	
	4552561	11-12-85	Eckenhoff	604	896	
	6280148	8-28-01	Roland et al.	417	44.1	
	2605765	8-5-52	Paul Kollsman	128	218	
	5957895	9-28-99	Sage et al.	604	181	
	5527288	6-18-96	Gross et al.	604	140	
	6302869	10-16-01	Klitgaard	604	218	
	6074369	6-13-00	Sage et al.	604	181	
	5169390	12-8-92	Amulya et al.	604	141	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
1177802	2-6-02	EP				
99/32174	7-1-99	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Hannele Yki-Jarvinen et al., New England Journal of Medicine, 1992, Vol. 327, Pages 1426-
2	Puhakainen I et. al., Diabetes Care, 1994, Vol. 17, Pages 805-809.
3	Kawamori et. al., Diabetes Care, 1989, Vol. 10, Pages 680-685

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.